Associated Papers
[Characterization of Genetic Polymorphisms Related to 5-FU Metabolizing Enzymes in Japanese Populations].
Hishinuma E
Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, 2026
Common dihydropyrimidinase ( DPYS ) genetic variations do not predict fluoropyrimidine-related chemotherapy toxicity in a Canadian cohort.
Medwid SJ et al.
Pharmacogenetics and Genomics, 2024
Functional Characterization of 12 Dihydropyrimidinase Allelic Variants in Japanese Individuals for the Prediction of 5-Fluorouracil Treatment-Related Toxicity.
Hishinuma E et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals, 2023
Identification of a novel variant in N-cadherin associated with dilated cardiomyopathy.
Chen Y et al.
Frontiers in Medicine, 2022
36111109 (PubMed )
Supplement: Table_3.XLSX › rare_varaints
Impact of DPYD, DPYS, and UPB1 gene variations on severe drug-related toxicity in patients with cancer.
Yokoi K et al.
Cancer Science, 2020
Whole-exome sequencing of 81 individuals from 27 multiply affected bipolar disorder families.
Forstner AJ et al.
Translational Psychiatry, 2020
32066727 (PubMed )
Supplement: 41398_2020_732_MOESM5_ESM.xlsx › Supplementary_Table_1
A case of dihydropyrimidinase deficiency incidentally detected by urine metabolome analysis.
Tsuchiya H et al.
Brain & Development, 2019
Mutational signatures and the genomic landscape of betel quid chewing-associated tongue carcinoma.
Zhang W et al.
Cancer Medicine, 2019
30672146 (PubMed )
Supplement: CAM4-8-701-s012.xlsx › Table_S11
Dihydropyrimidinase deficiency in four East Asian patients due to novel and rare DPYS mutations affecting protein structural integrity and catalytic activity.
Nakajima Y et al.
Molecular Genetics and Metabolism, 2017
Select a paper to view details